The Effect of Preoperative NLR Level on Epidural Analgesia Application in Thoracotomy

The aim of this study is to investigate the relationship of preoperative Neutrophil/Lymphocyte Ratio (NLR) with postoperative pain and the effect of preoperative NLR level on timing of epidural analgesia in thoracotomy.

Study Overview

• Status: Completed
• Conditions: C23.550.767.700; C23.550.470
• Intervention / Treatment: Diagnostic test: Neutrophil Lynphosite ratio

Detailed Description

The study was conducted prospectively in 60 patients aged 18-75 years, ASA I-III, who underwent thoracotomy. The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28). Each group was divided into subgroups with equal numbers of Prempative analgesia group and control group. Local anesthetic was administered to the preemptive analgesia group (Group P) 20 minutes before the surgical incision through the epidural catheter, and to the control group (Group K) 20 minutes before the patient was awakened from the epidural catheter. NRS levels and additional analgesia needs were recorded at 2, 4, 8, 12 and 24 hours postoperatively.

• Study Type: Observational
• Enrollment (Actual): 60

Contacts and Locations

Study Locations

• Turkey
  • Trabzon, Turkey
    • KaradenızTU

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

A total of 60 female and male patients aged 18-75 years, in the ASA I-III risk group, who will undergo elective thoracotomy

Description

Inclusion Criteria:

• Patient graded as American Society of Anesthesiologist (ASA) physical status, I, II or III
• Patient subjected to thoracotomy operation

Exclusion Criteria:

Patient having morbid obesity,

• Patient having renal failure,
• Patient having hepatic failure,
• Patient having neuropsychiatric disease,
• Patient allergy to the study drugs

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group A; Patients with NLR level below 2	Diagnostic test: Neutrophil Lynphosite ratio; The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
Group B; Patients with NLR level equal to or above 2	Diagnostic test: Neutrophil Lynphosite ratio; The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
preoperative neutrophil lymphoycte ratio	To determine the epidural application with preoperative neutrophil lymphoycte ratio	24 hours before the operation
Postoperative opioid requiremen Postoperative opioid requirement	Postoperative opioid requirement for pain relief	postoperative first 24 hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Numerical Pain Rating Scale	Numerical Pain Rating Scale in postoperative period	postoperative first 24 hour

Collaborators and Investigators

• Sponsor: Karadeniz Technical University

Study record dates

Study Major Dates

• Study Start (Actual): June 10, 2020
• Primary Completion (Actual): September 1, 2021
• Study Completion (Actual): January 10, 2022

Study Registration Dates

• First Submitted: January 10, 2022
• First Submitted That Met QC Criteria: January 22, 2022
• First Posted (Actual): January 27, 2022

Study Record Updates

• Last Update Posted (Actual): January 27, 2022
• Last Update Submitted That Met QC Criteria: January 22, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Preemptive Epidural Analgesia, Neutrophil/Lymphocyte Ratio, İnflammation
• Other Study ID Numbers: 2020/66

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No